deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT02272790

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor: AstraZeneca

Conditions Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Interventions Adavosertib Carboplatin Gemcitabine PLD Paclitaxel
Updated 32 times since 2017 Last updated: Oct 2, 2023 Started: Jan 30, 2015 Primary completion: Dec 13, 2018 Completion: Mar 8, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02272790, this PHASE2 trial focuses on Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation and remains completed. Sponsored by AstraZeneca, it has been updated 32 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 20 months · monthly snapshot

Change History

32 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Apr 2023 — Nov 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Feb 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 27 earlier versions

  1. Dec 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  7. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  10. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  11. Aug 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  12. May 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  13. Feb 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  14. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  15. Sep 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  16. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  17. Apr 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  18. Dec 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  19. Sep 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  20. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  21. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  22. Dec 2017 — May 2018 [monthly]

    Recruiting PHASE2

  23. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  24. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  25. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  26. Feb 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE2

  27. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Amsterdam, Netherlands , Augusta, United States , Boston, United States , Cleveland, United States , Dallas, United States , Detroit, United States , Gilbert, United States , La Jolla, United States , Los Angeles, United States and 9 more locations